The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis.

RATIONALE Idiopathic pulmonary fibrosis (IPF) is a fatal progressive interstitial pneumonia. The innate immune system provides a crucial function in the recognition of tissue injury and infection. Toll-like receptor 3 (TLR3) is an innate immune system receptor. We investigated the role of a functional TLR3 single-nucleotide polymorphism in IPF. OBJECTIVES To characterize the effects of the TLR3 Leu412Phe polymorphism in primary pulmonary fibroblasts from patients with IPF and disease progression in two independent IPF patient cohorts. To investigate the role of TLR3 in a murine model of pulmonary fibrosis. METHODS TLR3-mediated cytokine, type 1 IFN, and fibroproliferative responses were examined in TLR3 wild-type (Leu/Leu), heterozygote (Leu/Phe), and homozygote (Phe/Phe) primary IPF pulmonary fibroblasts by ELISA, real-time polymerase chain reaction, and proliferation assays. A murine model of bleomycin-induced pulmonary fibrosis was used in TLR3 wild-type (tlr3(+/+)) and TLR3 knockout mice (tlr3(-/-)). A genotyping approach was used to investigate the role of the TLR3 L412F polymorphism in disease progression in IPF using survival analysis and longitudinal decline in FVC. MEASUREMENTS AND MAIN RESULTS Activation of TLR3 in primary lung fibroblasts from TLR3 L412F-variant patients with IPF resulted in defective cytokine, type I IFN, and fibroproliferative responses. We demonstrate increased collagen and profibrotic cytokines in TLR3 knockout mice (tlr3(-/-)) compared with wild-type mice (tlr3(+/+)). TLR3 L412F was also associated with a significantly greater risk of mortality and an accelerated decline in FVC in patients with IPF. CONCLUSIONS This study reveals the crucial role of defective TLR3 function in promoting progressive IPF.

[1]  B. Moore,et al.  Viruses as co-factors for the initiation or exacerbation of lung fibrosis , 2008, Fibrogenesis & tissue repair.

[2]  A. Smahi,et al.  TLR3 Deficiency in Patients with Herpes Simplex Encephalitis , 2007, Science.

[3]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[4]  R. Hubbard,et al.  The rising incidence of idiopathic pulmonary fibrosis in the UK , 2011, Thorax.

[5]  K. Welsh,et al.  Analysis of Tumor Necrosis Factor- α , Lymphotoxin- α , Tumor Necrosis Factor Receptor II, and Interleukin-6 Polymorphisms in Patients with Idiopathic Pulmonary Fibrosis , 2001 .

[6]  W. Chung,et al.  Small Interfering RNAs Induce Macrophage Migration Inhibitory Factor Production and Proliferation in Breast Cancer Cells via a Double-Stranded RNA-Dependent Protein Kinase-Dependent Mechanism1 , 2008, The Journal of Immunology.

[7]  J. Stewart,et al.  Herpes Virus Infection Is Associated with Vascular Remodeling and Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis , 2013, PloS one.

[8]  A. Motala,et al.  Toll-like receptor 3 gene polymorphisms in South African Blacks with type 1 diabetes. , 2005, Tissue antigens.

[9]  D. Weissman,et al.  mRNA Is an Endogenous Ligand for Toll-like Receptor 3* , 2004, Journal of Biological Chemistry.

[10]  A. Gruber,et al.  Deletion of TLR3 Alters the Pulmonary Immune Environment and Mucus Production during Respiratory Syncytial Virus Infection , 2006, The Journal of Immunology.

[11]  F. Martinez,et al.  Recent advances in idiopathic pulmonary fibrosis. , 2007, Chest.

[12]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[13]  J. Norris,et al.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. , 2007, American journal of respiratory and critical care medicine.

[14]  D. Chaussabel,et al.  Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood , 2012, The Journal of experimental medicine.

[15]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[16]  S. Kunkel,et al.  TLR3 modulates immunopathology during a Schistosoma mansoni egg‐driven Th2 response in the lung , 2008, European journal of immunology.

[17]  N. Kaminski,et al.  Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern , 2007, PloS one.

[18]  J. Towbin,et al.  A Role for Toll-like Receptor 3 Variants in Host Susceptibility to Enteroviral Myocarditis and Dilated Cardiomyopathy* , 2010, The Journal of Biological Chemistry.

[19]  Ruslan Medzhitov,et al.  Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.

[20]  L. Leng,et al.  Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis. , 2012, American journal of respiratory and critical care medicine.

[21]  K. Brown,et al.  Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. , 2009, Chest.

[22]  R. Bucala.  Review Series - Inflammation & Fibrosis , 2012 .

[23]  B. Moore,et al.  Exacerbation of Established Pulmonary Fibrosis in a Murine Model by Gammaherpesvirus at a Glance Commentary , 2022 .

[24]  G. Parmigiani,et al.  Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. , 2008, The New England journal of medicine.

[25]  L. Fan,et al.  Toll‐like receptor 3 C1234T may protect against geographic atrophy through decreased dsRNA binding capacity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[27]  J. Mullol,et al.  Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[28]  B. Moore,et al.  Viral infection and aging as cofactors for the development of pulmonary fibrosis , 2010, Expert review of respiratory medicine.

[29]  B. Uhal,et al.  Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression , 2008, European Respiratory Journal.

[30]  Haitao Wen,et al.  TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events , 2008, The Journal of experimental medicine.

[31]  G. Raghu,et al.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[32]  E. B. Meltzer,et al.  Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44 , 2011, The Journal of experimental medicine.

[33]  D. Hyde,et al.  Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. , 1986, Biochemical medicine and metabolic biology.

[34]  T. Hara,et al.  Association of toll-like receptor 3 gene polymorphism with subacute sclerosing panencephalitis , 2011, Journal of NeuroVirology.

[35]  W. Miller,et al.  Effects of Single Nucleotide Polymorphisms on Toll-like Receptor 3 Activity and Expression in Cultured Cells* , 2007, Journal of Biological Chemistry.

[36]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[37]  O. Eickelberg,et al.  Molecular mechanisms of TGF‐β antagonism by interferon γ and cyclosporine A in lung fibroblasts , 2001 .

[38]  T. Sethi,et al.  Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach? , 2012, QJM : monthly journal of the Association of Physicians.

[39]  N. Kaminski,et al.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. , 2012, American journal of respiratory and critical care medicine.

[40]  B. Moore,et al.  Latent herpesvirus infection augments experimental pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[41]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[42]  W. Travis,et al.  Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[43]  N. Todd,et al.  Molecular and cellular mechanisms of pulmonary fibrosis , 2012, Fibrogenesis & tissue repair.

[44]  S. Donnelly.  Review Series--Inflammation & Fibrosis. Introduction. , 2012, QJM : monthly journal of the Association of Physicians.

[45]  S. Kudoh,et al.  Interferon-{beta} inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-{beta} and thrombospondin. , 2005, American journal of respiratory cell and molecular biology.

[46]  P. Sime,et al.  INVITED REVIEW SERIES: PULMONARY FIBROSIS , 2009 .

[47]  K. Brown,et al.  Clinical trials and tribulations--lessons from pulmonary fibrosis. , 2012, QJM : monthly journal of the Association of Physicians.

[48]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[49]  B. Berman,et al.  Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. , 1987, The Journal of clinical investigation.

[50]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[51]  K. Kawa,et al.  Epstein-Barr virus (EBV)–encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3 , 2009, The Journal of experimental medicine.

[52]  T. Moore,et al.  TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis , 2011, Fibrogenesis & tissue repair.